Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

Approximately three million people in Europe are affected by inflammatory bowel disease

- PMLiVE

LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab

The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer

- PMLiVE

Unlocking innovation: how generative AI and data are reshaping healthcare marketing

By Will Reese

- PMLiVE

Impactful Advances in Aesthetic Medicine

Medscape is pleased to announce new advancements within its Clinical Advances in Aesthetic Medicine. Launched in 2022, this initiative has effectively educated MD practitioners, showcasing measurable outcomes with submissions to...

Medscape Education

- PMLiVE

Sanofi’s Sarclisa granted EC approval to treat newly diagnosed multiple myeloma

Approximately 46,000 cases of the disease are expected to be diagnosed in Europe in 2025

- PMLiVE

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

More than 49,000 people are diagnosed with lung cancer in the UK each year

- PMLiVE

Chiesi report highlights incorrect inhaler use among UK asthma patients

The long-term lung condition affects around 7.2 million people in the UK

- PMLiVE

The power of purpose

Iona Everson from PMGroup speaks to Amar Urhekar, CEO of Avalere Health, about his professional journey within healthcare marketing and his commitment to building unconventional solutions that reach patients where...

- PMLiVE

A Pulse on Innovation at the Heart of Cardiology 2025

MedscapeLIVE! is proud to present its annual Heart of Cardiology meeting, returning for its fifth year in Miami, Florida from January 24-26, 2025. Over 3 packed days at the Fontainebleau...

Medscape Education

- PMLiVE

WHO launches $1.5bn emergency appeal to tackle ongoing health crises

The appeal is aimed at providing urgent humanitarian assistance to more than 300 million people

- PMLiVE

Novo shares promising results for high-dose semaglutide in late-stage obesity study

The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

- PMLiVE

Valneva shares positive phase 3 results for chikungunya vaccine in adolescents

The company has submitted label extension applications for Ixchiq in this age group

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links